DocMorris: Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life
(Berlin, Germany): – In January, Zur Rose Group announced its partnership with Novo Nordisk to raise awareness of obesity and to improve access to the right information, diagnosis and care for people living with this condition. Obesity (BMI >30) is a disease that affects a quarter of the adult German population (23% of men and 24% of women)1, a segment of the population at increased risk for many other serious diseases and health conditions like diabetes, cardiovascular diseases and musculoskeletal disorders2. To reduce the risk of health complications and improve their quality of life, people living with obesity share a need to reduce their weight, address the mental health implications of the disease and cope with the social stigmas associated to their condition. Today, the collaboration starts with the new web-based health experience and individual-relevant Hub: Adipositas Care supported by an insights-based obesity awareness campaign for people living with obesity.
“Thanks to our collaboration with Novo Nordisk, today marks the beginning of a new era for people living with obesity” says Betül Susamis Unaran, Chief Strategy and Digital Officer of the Zur Rose Group. “The new obesity health journey empowers people living with the condition by bringing forward a new way for them to access best possible care solutions, enabling them to get informed about their disease and linking them to online and offline specialized doctors and advisors in obesity care. The launch of this new health experience is a critical step in bringing Zur Rose Group’s ecosystem vision to life: in creating a world where everyone can manage their health in one click.”
Creating a new, individual relevant health experience
DocMorris Adipositas Care puts people with obesity in the center of the experience by addressing their key concerns. The hub release today is the first product version that will continue to be developed and improved over the next months. Features of the launch release include:
- Education that addresses weight loss, mental health, obesity stigmas and empowers people with obesity to take better healthcare decisions: The hub supports people with obesity to better understand their condition, the reasons behind their difficulty in losing and maintaining weight as well as the potential causes of obesity.
- Support on how to get started and ways to address top concerns: Guided by their most common concerns, the hub supports people living with obesity to access relevant content, treatment options adopted by peers and links to medical help and counseling.
- Discovery of best possible treatment options for this chronic condition: Many people living with obesity have tried various approaches to manage their weight and associated challenges. The hub enables them to discover possible treatment options such as medication, digital therapeutics and surgery provided by specialized healthcare professionals in obesity care.
- Link to specialized doctors and advisors in obesity: The hub enables access to specialized doctors online via a dedicated section at TeleClinic, Germany`s leading provider of telemedicine, and offline doctors and advisors via adipositas-spezialisten.de a tool to locate healthcare practitioners with obesity expertise in Germany.
A key step forward for the DocMorris European healthcare ecosystem
The DocMorris Adipositas Care hub anchors in the strategic expansion of the DocMorris brand – from pharmaceuticals to a consumer-centric digital healthcare platform, as the umbrella brand for the Zur Rose Group's European healthcare ecosystem.The new DocMorris Adipositas Care hub reflects Zur Rose Group’s vision of creating a world where everyone can get convenient access to health – anytime, anywhere, just one click away.
Experience DocMorris Adipositas Care here: www.docmorriscare.com/adipositas
[1] RKI DEGS 1 Study 2012. Available from:
https://www.rki.de/DE/Content/Gesundheitsmonitoring/Themen/Uebergewicht_Adipositas/Uebergewicht_Adipositas_node.html
[2] World Health Organization 2020, Obesity and overweight, United Nations. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [January 2021]
Contacts
Media contact
Segment Germany of the Zur Rose Group:
Torben Bonnke, Director Communication & PR
Email: torben.bonnke@docmorris.de, phone +49 30 21222 36 12
eHealth ecosystem contact
Betül Susamis Unaran, Chief Strategy and Digital Officer
Email: betul.unaran@zurrose.com, phone +41 79 834 41 40
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

